REVIEW
|
doi:10.20944/preprints202108.0037.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
ovarian cancer; checkpoint inhibitors; ICIs; immunotherapy; PARP; avelumab; pembrolizumab; nivolumab; bevacizumab; platinum
Online: 2 August 2021 (13:01:35 CEST)